

Republic of Moldova

Population 2018

4.1 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	3.5 (3–4)	86 (73–99)
HIV-positive TB incidence	0.3 (0.24–0.36)	7.4 (6–8.8)
MDR/RR-TB incidence ^{oo}	1.4 (1.1–1.6)	34 (28–40)
HIV-negative TB mortality	0.21 (0.18–0.23)	5.1 (4.5–5.8)
HIV-positive TB mortality	0.049 (0.036–0.065)	1.2 (0.88–1.6)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	29% (26–31)
Previously treated cases	60% (56–64)

TB case notifications, 2018

Total new and relapse	3 022
- % tested with rapid diagnostics at time of diagnosis	95%
- % with known HIV status	96%
- % pulmonary	91%
- % bacteriologically confirmed ^{ooo}	67%
- % children aged 0-14 years	3%
- % women	25%
- % men	72%
Total cases notified	3 465

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	7% (6–9)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	248	9%
- on antiretroviral therapy	168	68%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	97%
- Previously treated cases	80%
Laboratory-confirmed cases*	MDR/RR-TB: 927, XDR-TB: 111
Patients started on treatment**	MDR/RR-TB: 941, XDR-TB: 62
MDR/RR-TB cases tested for resistance to second-line drugs	765

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	81%	2 715
Previously treated cases, excluding relapse, registered in 2017	50%	176
HIV-positive TB cases registered in 2017	58%	204
MDR/RR-TB cases started on second-line treatment in 2016	53%	979
XDR-TB cases started on second-line treatment in 2016	26%	65

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	90% (83–99)

TB financing, 2019

National TB budget (US\$ millions)	37
Funding source: 88% domestic, 10% international, 2% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Total TB incidence
— New and relapse TB cases notified
— HIV-positive TB incidence

(Rate per 100 000 population per year)




— HIV-negative TB mortality

Notified cases by age group and sex, 2018




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically